Backgrounds/Aims: Cysteine dioxygenase type 1 (CDO1) acts as a tumor suppressor and is silenced by promoter methylation in various malignancies. The relationship between the CDO1 methylation status and hepatocellular carcinoma (HCC) tumorigenesis was evaluated. Methods: Using a HCC cell line (SNU423), an in vitro demethylation study was performed to confirm whether promoter methylation causes CDO1 down-regulation. The SNU423 cells transfected with the CDO1 cell function was compared to that of naïve cells. An in vivo study using immunohistochemical staining of HCC specimens that were collected from patients who underwent curative liver resection was also performed. Results: CDO1 was activated after demethylation treatment in the HCC specimens. Moreover, tumor cell proliferation, colony-forming, migration, and invasion activities significantly decreased after CDO1 transfection (p＜0.05). The percentage of tumors that were larger than 5 cm was higher in patients who had a lower expression of CDO1 (p=0.030). Vascular invasion and histological grade were independent prognostic factors for poor overall and recurrence-free survival. The degree of CDO1 expression was not an independent prognostic factor in this study's population. 
INTRODUCTION
Hepatocellular carcinoma (HCC) is a common malignancy and the fourth most common cause of cancer-related death in South Korea. HCC is difficult to treat and associated with poor prognoses and high mortality rates due to frequent recurrence. Many clinical factors, such as the advanced pathological tumor-node-metastasis (pTNM) stage and liver function status, are associated with the post-treatment prognosis. 1 In addition, many recent studies have demonstrated that there is a strong correlation between the cancer prognosis and genetic factors.
The term 'epigenetics' is used now to describe the study of stable alterations in gene expression potential that arise during cell development and proliferation. Epigenetic changes can induce an oncotic occurrence and development by altering the levels of gene expressions, even in the absence of variations in the DNA sequences of specific genes. 2 DNA methylation is the most common type of 'epigenetic change' and is the subject of much research.
Moreover, DNA methylation of tumor suppressor genes can be used as a biomarker to improve the clinical diagnosis or prognosis prediction in patients with cancer. [3] [4] [5] Cystein dioxygenase (CDO) is a non-heme structured, iron-containing metalloenzyme involved in the conversion of toxic cysteine to cysteine sulfate, and in taurine biosynthesis in mammals. 6 There are two types of CDO Therefore, the aim of this study was to identify correlations between CDO1 methylation and HCC, using HCC cell lines, and to confirm whether CDO1 methylation status is relevant to the prognosis of patients with HCC. We used GAPDH-specific primers as an internal control:
MATERIALS AND METHODS

Cell lines and culture conditions
R-TGCTGTAGCCAAATTCGTTG and F-GTCAGTGGT GGACCTGACCT.
Demethylation test in vitro
The Cell migration assay Migration assays were performed using a 35-mm -dish (ibidi, Martinsried, Germany) according to the manufacturer's protocol. Briefly, the 5×10 5 cells were placed into two-chamber cell culture inserts in -dishes. After cell attachment, the culture inserts were gently removed and cell migration was evaluated by light microscopy at the indicted time intervals. All assays were performed in triplicates.
Western blot analysis
Cell invasion assay
The cell invasion assay was performed using a 24-well 
RESULTS
Demethylation assays
CDO1 expression was enhanced in all of the HCC cell lines following demethylation treatment. However, the de- gree of gene expression varied (Fig. 1) . Thus, the downregulation of CDO1 in the HCC cells was due to epigenetic methylation. Among the HCC cell lines tested, the SNU423 cell line was selected for further experiments.
Effects of CDO1 over-expression on cell proliferation, colony-forming, migration, and invasion activities To study the tumor-suppressive capacity of CDO1, CDO1 was transfected into a CDO1-suppressed HCC cell line (SNU423). CDO1 overexpression was confirmed by western blotting (Fig. 2A) . A subsequent analysis revealed that the proliferation, colony-forming, migration, and invasion activities of the HCC cells were suppressed by CDO1 overexpression compared with the control cells (Figs. 2B, 2C, 2D , and 2E). 
Immunohistochemical staining of the CDO1 protein in HCC specimens
The CDO1 protein staining intensity varied greatly between the HCC tissues. The representative images of the various staining intensities are displayed in Fig. 3 . A dot plot of staining intensity and the proportions of stained cells in each HCC tissue was generated (Fig. 4) . The number of patients with a staining intensity with a grade of 0-1 was 121 (66.5%), and the number of patients with less than 50% of stained cells was 104 (57.1%). Thus, CDO1
protein expression was suppressed in the majority of the HCC tissues (Fig. 4) . Based on this analysis, patients were divided into two groups according to IH index value; 150 patients had an IH index of 100 or less; whereas 32 patients exhibited an IH index of greater than 100. Notably, an IH index of 100 or less was significantly associated with an HCC size of greater than 5 cm (47.3% versus 28.1%, respectively; p=0.030) ( Table 1 ). The independent risk factors that affected overall survival were microvascular (p ＜0.001) and macrovascular invasions (p=0.020). In addition, the independent risk factors that affected HCC recurrence were microvascular invasion (p＜0.001), macrovascular invasion (p=0.023), histologic grade (p=0.005), and a tumor size of more than 5 cm (p=0.035). However, the degree of CDO1 protein expression was not an independent risk factor for overall or recurrence-free survival.
DISCUSSION
DNA methylation is a key mechanism that inhibits the expression of tumor-suppressor genes and the most fre-quently studied epigenetic alteration.
3 CG-rich regions, known as cytosine-phosphate-guanine (CpG) islands, are located within 5ʹ of the ends of genes, which includes the promoter region, untranslated region, and first exon, and can affect the activity of tumor-suppressor genes. 13 The
CpG islands are not usually methylated in healthy cells 13 ;
however, aberrant hypermethylation of the CpG islands, which leads to transcriptional inactivation and gene silencing, is a frequent early event in carcinogenesis and considered a common mechanism of the loss of the tumor-suppressor gene function in human cancers. 3, 14 Epigenetic alterations, such as DNA methylation, are thought to predispose an individual to genetic alterations during tumorigenesis. Furthermore, the hypermethylation of tumor-suppressor genes is associated with tumor cell proliferation, migration, invasion, and colony formation.
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For example, the promoter CpG island methylation of CDO1 has been found in multiple tumor types, including breast, esophagus, lung, bladder, and stomach cancer 8 ;
however, to date, no reports have described studies of CDO1 methylation in HCC tissues and cell lines.
The development and progression of HCC is a multi-step process that involves a sequence that ranges from chronic hepatitis to cirrhosis to HCC. 16 Moreover, the aberrant methylation of tumor-suppressor genes may play an important role in the course of this multi-step hepatocarcinogenesis. 17 Hu et al. 18 reported that reduced phosphatase and tensin homolog (PTEN) expression levels are involved in the pathogenesis of HCC and that decreased PTEN expression is correlated with tumor progression, high alpha-fetoprotein levels, p53 overexpression, and poor prognosis in patients with HCC.
Nishida et al. 17 reported an analysis of multiple tumor-suppressor genes, including HIC-1, CDH1, and MINT1, and Um et al. 19 also reported a study of multiple genes, including APC, SOCS1, and COX2, and concluded that a general stepwise increase in methylation events occurred during a hepatitis B virus-related multistep hepatocarcinogenesis. Additionally, epigenetic changes may occur predominantly in the early stages of HCC development. 19 In this study, CDO1 expression was suppressed in the HCC cell lines and was increased after treatment with the demethylation agent, 5-Aza-dC. Thus, the suppression of CDO1 expression occurred through promoter methylation.
We confirmed that the overexpression of CDO1 strongly inhibited cell proliferation, colony-forming, migration, and invasion activities in the HCC cell lines. We also demonstrated that CDO1 expression was suppressed in the HCC tissues that were collected from patients who had undergone liver resection. These findings implied that promoter methylation may lead to the suppression of CDO1 expression in HCC tissues.
Indeed, this study demonstrated that Additionally, epigenetic changes such as DNA methylation may occur predominantly in the early stages of HCC development. 20 Therefore, CDO1 expression has a high probability of influencing the early steps of tumorigenesis in HCC, and we inferred that the degree of CDO1 expression was not an independent factor for HCC patient prognosis.
In conclusion, our results suggested that methylation down-regulated the expression of CDO1 in HCC cells and that CDO1 methylation may be a valuable diagnostic biomarker for HCC. However, the key regulatory mechanisms through which CDO1 may exert its tumor-suppressive functions are still unknown. Therefore, further studies are needed to assess these mechanisms.
